Equities analysts predict that Insulet Co. (NASDAQ:PODD) will announce earnings of ($0.07) per share for the current quarter, according to Zacks Investment Research. Ten analysts have issued estimates for Insulet’s earnings, with the highest EPS estimate coming in at ($0.01) and the lowest estimate coming in at ($0.15). Insulet posted earnings per share of ($0.16) in the same quarter last year, which indicates a positive year over year growth rate of 56.3%. The company is scheduled to announce its next quarterly earnings results on Monday, February 26th.

On average, analysts expect that Insulet will report full-year earnings of ($0.42) per share for the current fiscal year, with EPS estimates ranging from ($0.50) to ($0.35). For the next fiscal year, analysts forecast that the company will post earnings of ($0.17) per share, with EPS estimates ranging from ($0.62) to $0.30. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Insulet.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported ($0.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.06. Insulet had a negative return on equity of 43.85% and a negative net margin of 6.66%. The firm had revenue of $121.80 million for the quarter, compared to the consensus estimate of $114.02 million. During the same quarter last year, the business posted ($0.05) earnings per share. The firm’s revenue was up 28.4% compared to the same quarter last year.

A number of equities research analysts have commented on the company. Jefferies Group restated a “buy” rating and issued a $58.00 target price (up previously from $48.00) on shares of Insulet in a research report on Wednesday, August 9th. BidaskClub downgraded Insulet from a “buy” rating to a “hold” rating in a research report on Saturday. Canaccord Genuity reiterated a “hold” rating and issued a $50.00 price objective on shares of Insulet in a report on Wednesday, September 27th. Barclays boosted their price objective on Insulet from $70.00 to $75.00 and gave the company an “overweight” rating in a report on Monday, November 20th. Finally, Robert W. Baird boosted their price objective on Insulet from $65.00 to $72.00 and gave the company an “outperform” rating in a report on Friday, November 3rd. Eight investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $61.07.

Shares of Insulet (PODD) opened at $69.49 on Wednesday. Insulet has a 1 year low of $35.12 and a 1 year high of $72.99. The company has a debt-to-equity ratio of 4.65, a current ratio of 4.88 and a quick ratio of 4.42.

In other news, Director James C. Mullen bought 2,500 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was purchased at an average cost of $67.45 per share, with a total value of $168,625.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 2.60% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Insulet by 11.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,302 shares of the medical instruments supplier’s stock worth $118,000 after buying an additional 235 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Insulet during the 2nd quarter worth approximately $180,000. Wrapmanager Inc. purchased a new position in shares of Insulet during the 2nd quarter worth approximately $217,000. RNC Capital Management LLC purchased a new position in shares of Insulet during the 2nd quarter worth approximately $225,000. Finally, Trexquant Investment LP purchased a new position in shares of Insulet during the 3rd quarter worth approximately $242,000.

COPYRIGHT VIOLATION NOTICE: “-$0.07 EPS Expected for Insulet Co. (PODD) This Quarter” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/06/0-07-eps-expected-for-insulet-co-podd-this-quarter.html.

Insulet Company Profile

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Get a free copy of the Zacks research report on Insulet (PODD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Co. and related companies with MarketBeat.com's FREE daily email newsletter.